A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Completed · Phase 3 · NCT05931367
Conditions: Obesity, Overweight, Osteo Arthritis Knee
At a glance
- Research payments reported, 2025
- $1.8M
- U.S. investigators named
- 21
- Sites paid
- 17
- Planned or actual enrollment
- 445
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Retatrutide (drug), Placebo (drug)
- Dates
- Started 2023-08-01; completion 2025-11-14
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.8M in research payments for this study in 2025 (38 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Louise A. Taber, M.D. Internal Medicine · Phoenix, AZ
- Stacey L. Layle, MD Family Medicine · San Diego, CA
- Jenna E. Langello, PA-C Physician Assistants · Waterbury, CT
- Mark E. Kutner, MD Internal Medicine · Miami, FL
- Bram Wieskopf, MD Internal Medicine · Woodstock, GA
- Gary W. Soucie, MD Family Medicine · Blackfoot, ID
- Thomas J. Schnitzer, MD, PHD Sports Medicine · Chicago, IL
- David J. Dibenedetto, M.D. Pain Medicine · Waltham, MA
- Jeffrey A. Potts, MD Internal Medicine · Bay City, MI
- Andrew N. Abboud Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Agam Bansal, MD Internal Medicine · Cleveland, OH
- Vincent Chen, MD Cardiology · Cleveland, OH
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Andre Barkhuizen, M.D. Rheumatology · Portland, OR
- Samuel Kelly, MD Cardiology · Philadelphia, PA
- Ebere I. Azubuike, MD Family Medicine · Dallas, TX
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
- Gaylon Kipp, MD Family Medicine · Bellevue, WA
- Nazia H. Rahman, M.D. Pediatrics · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- North Georgia Clinical Research $408,644
- Great Lakes Research Group Inc $390,589
- Northwest Clinical Research Center $228,694
- Medvadis Research Corp LLC $142,356
- Artemis Headlands LLC $126,384
- Northwestern University $100,218
- Biopharma Informatic Inc $99,887
- Suncoast Research $95,865
- Chase Medical Research LLC $53,949
- Clinvest Headlands LLC $45,631
- Arizona Research Center $39,882
- Elite Clinical Trials Lllp $28,040
- Clinical Trials of Texas Inc $26,683
- Cleveland Clinic, OH $710
- Suncoast Clinical Research $405
- Clinvest Research LLC $195
- Banyan Group Inc $105
- $18
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.